微小核糖核酸与抗血小板药物反应异质性的相关研究进展

Micro ribonucleic acid in relation to the heterogeneous reactivity of antiplatelet drugs:progress and perspectives

摘要:

抗血小板药物在心脑血管血栓性疾病的防治过程中发挥核心作用,但存在药物反应异质性所致的严重缺血/出血风险。寻找能够预测抗血小板药物反应性个体差异的生物标志物,对于个体化应用抗血小板药物具有重要的临床价值。近年研究发现,血小板蕴含丰富的微小核糖核酸(microRNA),其中具有调控血小板P2Y12受体编码基因(P2RY12)表达的microRNA与P2Y12受体拮抗剂抗血小板反应性的相关性备受关注。本文将针对与抗血小板药物反应性相关的血小板microRNA的生物学特征、相关性研究和可能机制作一综述。

Abstract:

Antiplatelet drugs play an established role in the prevention and treatment of cardiovascular and cerebrovascular events associated with atherothrombosis, but heterogeneous reactivity poses risks of serious ischemia or bleeding. Finding predictive biomar-kers of the heterogeneous reactivity of antiplatelet drugs is of great clinical value for their personalized use. Studies in recent years have found that platelets are a major source of miRNA, and much attention has been attracted to correlation between the platelet miRNA that can potentially regulate the expression of platelet P2Y12 and antiplatelet reactivity of P2Y12 receptor antagonists. This paper reviews the biological characteristic, correlation studies, and possible mechanisms of platelet microRNA in relation to reactivity of antiplatelet drugs.